Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells

Q. Chen; H. Kaji; M. Kanatani; T. Sugimoto; K. Chihara

doi:10.1055/s-2004-826013

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2004; 36(10): 674-678
DOI: 10.1055/s-2004-826013

Original Basic

Testosterone Increases Osteoprotegerin mRNA Expression in Mouse Osteoblast Cells

Q. Chen¹ , H. Kaji¹ , M. Kanatani¹ , T. Sugimoto¹ , K. Chihara¹

¹Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine

Abstract

The role that androgens play in the regulation of bone metabolism has been substantiated in animals and humans. We previously demonstrated that testosterone inhibits osteoclast differentiation stimulated by parathyroid hormone through the androgen receptor in mouse bone-cell cultures. However, the details of this mechanism are still unknown. The present study was aimed at examining whether testosterone would affect the mRNA levels of osteoprotegerin (OPG) and receptor activator of NfκB ligand (RANKL) in mouse bone-cell cultures as well as mouse osteoblastic cell-line, MC3T3-E1 cells by employing semi-quantitative RT-PCR. Testosterone increased OPG mRNA expression in both mouse bone-cell cultures and MC3T3-E1 cells. 10-8 M PTH-(1-34) as well as 10-8M 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] inhibited OPG mRNA expression in mouse bone cells. 10-8 M testosterone antagonized OPG mRNA expression inhibited by 10-8 M PTH-(1-34), but failed to affect OPG mRNA expression inhibited by 10-8 M 1,25(OH)2D3. 10-8 M α-dehydrotestosterone, a non-aromatizable androgen, increased OPG mRNA expression. On the other hand, testosterone did not affect RANKL mRNA expression in MC3T3-E1 or mouse bone cells. In conclusion, the present study demonstrated that testosterone increased OPG mRNA expression in mouse bone-cell cultures and the osteoblastic cell line. These effects are likely to take place through the androgen receptor.

Keywords

Androgen - Osteoblast - Osteoprotegerin

Full Text

References

1 Orwoll E S, Klein R F. Osteoporosis in men. Endocr Rev. 1995; 16 87-116
2 Seeman E, Melton L J , O’Fallon W M, Riggs B L. Risk factors for spinal osteoporosis in men. Am J Med. 1983; 75 977-983
3 Francis R M. The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf). 1999; 50 411-414
4 Vanderschueren D, Vandenput L, Boonsen S, van Herck E, Swinnen J V, Bouillon R. An aged rat model of partial androgen deficiency: prevention of both loss of bone and lean body mass by low-dose androgen replacement. Endocrinology. 2000; 141 1642-1647
5 Tobias J H, Gallagher A, Chambers T J. 5-alpha-Dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol. 1994; 267 E853-859
6 Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo Y, Nakamura T, Ouchi Y, Chan C, Orimo H. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int. 1994; 54 325-329
7 Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg T C, Riggs B L, Oursler M J. Androgen regulates bone resorption activity of isolated osteoclasts in vitro. Proc. Natl Acad. Sci. USA. 1999; 96 505-510
8 Kaji H, Sugimoto T, Kanatani M, Nasu M, Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Endocrinology. 1996; 137 2217-2224
9 Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Letter. 2001; 491 91-93
10 Simonet W S, Lacey D L, Dunstan C R, Kelley M, Chang M S, Luthy R, Nguyen H Q, Wooden S, Bennet L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes T M, Hill D, Pattison W, Campbell P, Boyle W J. Osteoprotegrin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89 309-319
11 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashino K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95 3597-3602
12 Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997; 12 869-879
13 Saika M, Inoue D, Kido S, Matsumoto T. 17 beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology. 2001; 142 2205-2212
14 Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsberg T C, Riggs B L. Estrogen stimulates gene expression and protein production of osteoprotegrin in human osteoblastic cells. Endocrinology. 1999; 140 4367-4370
15 Kaji H, Sugimoto T, Kanatani M, Miyauchi A, Kimura T, Sakakibara S, Fukase M, Chihara K. Carboxyl-terminal parathyroid hormone fragments stimulates osteoclast-like cell formation and osteoclastic activity. Endocrinology. 1994; 134 1897-1904
16 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162 156-159
17 Hornood N J, Elliott J, Martin T J, Gillespie M T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegrin in osteoblastic stromal cells. Endocrinology. 1998; 139 4743-4746
18 Colvard D S, Eriksen E F, Keeting P E, Wilson E M, Lubahn D B, French F S, Riggs B L, Spelsberg T C. Identification of androgen receptors in normal human osteoblast-like cells. Pro Natl Acad Sci USA. 1989; 86 854-857
19 Schweikert H U, Rulf W, Niederle N, Schafer H E, Keck E, Kruck F. Testosterone metabolism in human bone. Acta Endocrinol (Copenh). 1980; 95 258-264
20 Huber D M, Bendixen A C, Pathrose P, Strivastava S, Dienger K M, Shevde N K, Pike J W. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology. 2001; 142 3800-3808
21 Bellido T, Jilka R L, Boyce B F, Girasole G, Broxmeyer H, Dalrymple S A, Murray R, Manolagas S C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995; 95 2886-2895
22 Hofbauer L C, Hicok K C, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J Cell Biochem. 1998; 71 96-108
23 Kasperk C, Fitzsimmons R, Strong D, Mohan S, Jennings J, Wergedal J, Baylink D. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab. 1990; 71 1322-1329
24 Anderson F H, Francis R M, Hindmarsh P, Fall C, Cooper C. Osteoporosis ’96 (Papapoulous SE, Lips P, Pols HAP, Johnston CC, Delmas PD, Eds). Amsterdam; Elsevier 1996: 377-381
25 Slemenda C, Longcope C, Zhou L, Hui S L, Peacock M, Johnston C C. Sex steroids and bone mass in older man. Positive associations with serum estrogens and negative associations with androgens. J Clin Invwst. 1997; 100 1755-1759
26 Anderson F H, Francis R M, Selby P L, Cooper C. Sex hormones and osteoporosis in men. Clacif Tissue Int. 1998; 62 185-188
27 Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach K S, Simpson E R. Effects of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997; 337 91-95
28 Smith E P, Boyd J, Frank G R, Takahashi H, Cohen R M, Specker B, Williams T C, Lubahn D B, Korach K S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994; 331 1056-1061
29 Hofbauer L C, Khosla S. Androgen effects on bone metabolism: recent progress and controversies. Eur J Endocrinol. 1999; 140 271-286
30 Vanderschueren D, Boonen S, Bouillon R. Action of androgen versus estrogens in male skeletal homeostasis. Bone. 1998; 23 391-394
31 Vandenput L, Ederveen A G, Erben R G, Stahr K, Swinnen J V, van Herck E, Verstuyf A, Boonen S, Bouillon R, Vanderschueren D. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem Biophys Res Commun. 2001; 285 70-76
32 Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S. Suppressive function of androgen receptor in bone resorption. Pro Natl Acad Sci USA. 2003; 100 9416-9421
33 Hofbauer L C, Hicok K C, Chen D, Khosla S. Regulation of osteoprotegrin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol. 2002; 147 269-273

Toshitsugu Sugimoto, M.D.

Division of Endocrinology/Metabolism · Neurology and Hematology/Oncology · Department of Clinical Molecular Medicine · Kobe University Graduate School of Medicine

7-5-2 Kusunoki-cho · Chuo-ku · Kobe 650-0017 · Japan

Phone: +81(78)38258 85

Fax: +81(78)3825899